BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol. 2012;67:1349-1361. [PMID: 22727462 DOI: 10.1016/j.jaad.2012.04.036] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Wu D, Gu Q, Zhao N, Xia F, Li Z. Structure-based rational design of peptide hydroxamic acid inhibitors to target tumor necrosis factor-α converting enzyme as potential therapeutics for hepatitis. J Drug Target 2015;23:936-42. [PMID: 26061299 DOI: 10.3109/1061186X.2015.1043916] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
2 Ting SW, Chen YC, Huang YH. Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab. Clin Drug Investig. 2018;38:873-880. [PMID: 29968197 DOI: 10.1007/s40261-018-0671-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
3 Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-244. e3. [PMID: 25447852 DOI: 10.1053/j.gastro.2014.10.038] [Cited by in Crossref: 274] [Cited by in F6Publishing: 249] [Article Influence: 34.3] [Reference Citation Analysis]
4 Steglich RB, Meneghello LP, Carvalho AV, Cheinquer H, Muller FM, Reginatto FP. The use of ustekinumab in a patient with severe psoriasis and positive HBV serology. An Bras Dermatol. 2014;89:652-654. [PMID: 25054756 DOI: 10.1590/abd1806-4841.20143013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
5 Ahn CS, Dothard EH, Garner ML, Feldman SR, Huang WW. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2015;73:420-428.e1. [PMID: 26184440 DOI: 10.1016/j.jaad.2015.06.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
6 Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013;169:1295-1303. [PMID: 23746170 DOI: 10.1111/bjd.12461] [Cited by in Crossref: 87] [Cited by in F6Publishing: 69] [Article Influence: 10.9] [Reference Citation Analysis]
7 Sanz-Bueno J, Vanaclocha F, García-Doval I, Torrado R, Carretero G, Daudén E, Patricia Ruiz-Genao D, Alsina-Gibert MM, Pérez-Zafrilla B, Pérez-Rial G. Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database. Actas Dermosifiliogr. 2015;106:477-482. [PMID: 25776200 DOI: 10.1016/j.ad.2015.01.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
8 Vilarrasa E, Puig L. Psoriasis: Biologic treatment and liver disease. World J Dermatol 2014; 3(4): 76-85 [DOI: 10.5314/wjd.v3.i4.76] [Cited by in CrossRef: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Fiore M, Leone S, Maraolo AE, Berti E, Damiani G. Liver Illness and Psoriatic Patients. Biomed Res Int 2018;2018:3140983. [PMID: 29546055 DOI: 10.1155/2018/3140983] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
10 Piaserico S, Dapavo P, Conti A, Gisondi P, Russo FP. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017;31:1853-1859. [PMID: 28146345 DOI: 10.1111/jdv.14146] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
11 Ly K, Smith MP, Thibodeaux Q, Beck K, Bhutani T, Liao W. Dupilumab in patients with chronic hepatitis B on concomitant entecavir. JAAD Case Rep 2019;5:624-6. [PMID: 31341942 DOI: 10.1016/j.jdcr.2019.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents. Clin Liver Dis 2019;23:521-34. [PMID: 31266625 DOI: 10.1016/j.cld.2019.04.012] [Reference Citation Analysis]
13 Vassilopoulos D, Calabrese LH. Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV. Curr Rheumatol Rep. 2013;15:319. [PMID: 23436024 DOI: 10.1007/s11926-013-0319-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
14 Chirch LM, Cataline PR, Dieckhaus KD, Grant-kels JM. Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor–alfa antagonists. Journal of the American Academy of Dermatology 2014;71:1.e1-8. [DOI: 10.1016/j.jaad.2014.01.875] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Sanz-bueno J, Vanaclocha F, García-doval I, Torrado R, Carretero G, Daudén E, Patricia Ruiz-genao D, Alsina-gibert M, Pérez-zafrilla B, Pérez-rial G, Rivera R. Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database. Actas Dermo-Sifiliográficas (English Edition) 2015;106:477-82. [DOI: 10.1016/j.adengl.2015.05.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Lunel-Fabiani F, Masson C, Ducancelle A. Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. Joint Bone Spine. 2014;81:478-484. [PMID: 24561021 DOI: 10.1016/j.jbspin.2014.01.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
17 Mansouri B, Patel M, Menter A. Biological therapies for psoriasis. Expert Opin Biol Ther. 2013;13:1715-1730. [PMID: 24160990 DOI: 10.1517/14712598.2013.853739] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
18 Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol 2016; 22(28): 6444-6455 [PMID: 27605880 DOI: 10.3748/wjg.v22.i28.6444] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
19 Manalo IF, Gilbert KE, Wu JJ. Preventing hepatitis B reactivation associated with immunosuppressive drug treatments for psoriasis. Journal of the American Academy of Dermatology 2015;73:881-2. [DOI: 10.1016/j.jaad.2015.07.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
20 Steglich RB, Meneghello LP, Carvalho AV, Cheinquer H, Muller FM, Reginatto FP. The use of ustekinumab in a patient with severe psoriasis and positive HBV serology. An Bras Dermatol. 2014;89:652-654. [PMID: 25054756 DOI: 10.1590/abd1806-4841.2014301] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Gisondi P, Altomare G, Ayala F, Bardazzi F, Bianchi L, Chiricozzi A, Costanzo A, Conti A, Dapavo P, De Simone C. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31:774-790. [PMID: 28244153 DOI: 10.1111/jdv.14114] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 14.6] [Reference Citation Analysis]
22 Carrascosa JM, Del-alcazar E. New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management. Expert Review of Clinical Immunology 2018;14:259-73. [DOI: 10.1080/1744666x.2018.1454835] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
23 Kłujszo EH, Zarębska-Michaluk D, Kręcisz B, Witkowska A. Safety of therapies using ustekinumab in patients with psoriasis who have had hepatitis B virus infection. Dermatol Ther 2021;:e15274. [PMID: 34921578 DOI: 10.1111/dth.15274] [Reference Citation Analysis]
24 Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019;80:1029-72. [PMID: 30772098 DOI: 10.1016/j.jaad.2018.11.057] [Cited by in Crossref: 197] [Cited by in F6Publishing: 158] [Article Influence: 65.7] [Reference Citation Analysis]
25 Zhao Y, Lai W. Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab. Patient Prefer Adherence 2014;8:865-72. [PMID: 24971001 DOI: 10.2147/PPA.S40638] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
26 Orlicka K, Barnes E, Culver EL. Prevention of infection caused by immunosuppressive drugs in gastroenterology. Ther Adv Chronic Dis. 2013;4:167-185. [PMID: 23819020 DOI: 10.1177/2040622313485275] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
27 Matsutani M, Imai Y, Nakatani‐kusakabe M, Natsuaki M, Yamanishi K, Kanazawa N. Dupilumab in atopic dermatitis patients with chronic hepatitis B. J Cutaneous Imm & Allergy 2022;5:65-6. [DOI: 10.1002/cia2.12209] [Reference Citation Analysis]
28 Wu JJ, Merola JF, Feldman SR, Menter A, Lebwohl M. Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence. Dermatol Ther (Heidelb) 2020;10:351-64. [PMID: 32242325 DOI: 10.1007/s13555-020-00373-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]